Remove Capital Raising Remove IPO Remove Valuation
article thumbnail

Past Event: SPACs: The Next Gen IPO or Just a Fad?

Cooley M&A

Market volatility, a low interest rate environment and disillusionment with the IPO process, have made SPACs an attractive alternative for private companies looking to go public in recent months. According to Odeon Capital Group research, as of December 2, 2020, 210 SPAC IPOs had been completed representing gross proceeds of ~$72 billion.

IPO 52
article thumbnail

Event-Driven Hedge Funds: The Best Home for Bankers Turned Investors?

Mergers and Inquisitions

They have their investment thesis and valuation, and the earnings announcement is the event that unlocks value… …but this is not what “event-driven” means in most cases. But if we’re wrong, and the spin-off doesn’t happen or gets done at a lower valuation, the parent company’s share price would fall by only 10%.”

Funds 64
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

M&A Heats Up in the Bakery Market

Focus Investment Banking

Healthy competition for the top bakeries has increased valuations in recent years, with strong purchase price / cash flow (EBITDA) multiples. Jim has worked on numerous IPOs, sell-side transactions, fairness opinions, and capital raises, mainly for consumer products companies and restaurants.

M&A 52
article thumbnail

Top 3 Growth Financing Options for Software Companies

Software Equity Group

Minority investors aim to increase value and earn a return on their investment when your business undergoes additional transactions down the line, whether through additional capital raises, acquisition, or an initial public offering (IPO). Hiring an advisor for your growth financing helps ensure a successful transaction.

Finance 52
article thumbnail

Biotech Hedge Funds: A Match Made in Heaven

Mergers and Inquisitions

In technology, as a startup keeps raising capital, it normally does so at gradually higher valuations as its customers, users, and revenue grow. But in biotech, companies valuations often remain close to their total capital raised until much later in the process (i.e., or Ph.D.),

Funds 64